Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. Greetings and welcome to Inhibit Case Therapeutics' fourth quarter and full year 2023 financial results. At this time, all participants will be in listen-only mode. The question and answer session will follow the formal presentation. Please note that today's conference is being recorded, and if you should require operator assistance, you may press star zero from your telephone keypad. I'll now turn the call over to Alex Lobo, Stern Investor Relations. Alex, you may now begin. Thank you, operator. Good morning and welcome to Inhibit Case Therapeutics' fourth quarter and full year 2023 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer, and Garth Lees-Ross, Chief Financial Officer. On March 27th, Inhibit Case issued a press release announcing financial results for the fourth quarter and full year ended December 31st, 2023. We encourage everybody to read yesterday's press release as well as Inhibit Case's annual report on Form 10-K. which has been filed with the SEC. The company's press release and annual report are also available on Inhibicase's website at inhibicase.com. In addition, this conference call is being webcast through the investor relations section of the company's website and will be archived there for future reference. Please note that certain information discussed on today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, March 28, 2024. Actual results could differ materially from those stated or implied by these forward-looking statements d...